Trial Profile
A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2021
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Aggression; Agitation
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 22 Apr 2021 Results assessing pimavanserin's impact on cognitive measures in patients with neuropsychiatric manifestations of neurodegenerative disease in 4 studies (019, 032, 046 & HARMONY), presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 07 Mar 2019 Status changed to discontinued.
- 16 Mar 2018 Status changed from active, no longer recruiting to completed.